Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

X
Trial Profile

A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talimogene laherparepvec (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pegfilgrastim
  • Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
    • 29 Sep 2021 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
    • 08 Jun 2021 Results (n=40) reporting efficacy and safety from phase II portion of this simon 2 stage trial presented at the 57th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top